ANEB - NASDAQ

Anebulo Pharmaceuticals, Inc.

ANEB·NASDAQ

$1.72

-33%

HealthcareBiotechnology

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$70.67M

EPS-0.2500

P/E Ratio-5.74

Earnings Date02/12/2026

12.15M

Assets

198%

3Y-22.0%

5Y+301.0%

10Y+301.0%

487.69K

Total Liabilities

87%

3Y-5.0%

5Y-85.0%

10Y-85.0%

11.66M

Total Equity

206%

3Y-23.0%

5Y-6912.0%

10Y-6912.0%

Anebulo Pharmaceuticals, Inc. Funding & Solvency Profile

ANEB · NASDAQ

Current Assets

Cash & Cash Equivalents11.63M

Net Receivables73.22K

Inventory0.00

Other Current Assets0.00

Total Current Assets12 M

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets183.11K

Total Non-Current Assets183 K

Total Assets

12.15M

Financial Health Analysis

Current Ratio

53.36x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.04x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

12 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

98% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Anebulo Pharmaceuticals, Inc. Balance Sheet

ANEB • NASDAQ

Anebulo Pharmaceuticals, Inc. Balance Sheet	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	11.6M	3.1M	11.2M	14.5M	20M	3M
Cash & Short-Term Investments	11.6M	3.1M	11.2M	14.5M	20M	3M
Net Receivables	73.2K	0.0	0.0	0.0	0.0	3.5K
Other Receivables	73.2K	0.0	0.0	0.0	0.0	3.5K
Inventory	0.0	0.0	0.0	0.0	0.0	-3.0
Prepaids	261.4K	413.8K	0.0	0.0	0.0	0.0
Total Current Assets	12M	3.5M	11.2M	14.5M	20M	3M
NON-CURRENT ASSETS
Other Non-Current Assets	183.1K	565.1K	0.0	0.0	0.0	0.0
Total Non-Current Assets	183.1K	565.1K	0.0	1M	1.7M	0.0
Other Assets	0.0	0.0	422.7K	0.0	0.0	0.0
Total Assets	12.1M	4.1M	11.7M	15.6M	21.7M	3M
LIABILITIES
CURRENT LIABILITIES
Total Payables	224.2K	156.4K	534.5K	380.8K	110K	0.0
Accounts Payable	224.2K	156.4K	534.5K	380.8K	110K	0.0
Accrued Expenses	263.5K	104.2K	534.3K	131.7K	131.6K	22.6K
Short Term Debt	0.0	0.0	0.0	0.0	0.0	201.3K
Other Current Liabilities	-263.5K	0.0	0.0	0.0	0.0	0.0
Total Current Liabilities	224.2K	260.6K	534.5K	512.5K	241.6K	223.9K
NON-CURRENT LIABILITIES
Other Non-Current Liabilities	263.5K	0.0	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	263.5K	0.0	534.3K	380.8K	131.6K	3M
Other Liabilities	0.0	0.0	0.0	-380.8K	-131.6K	0.0
Total Liabilities	487.7K	260.6K	1.1M	512.5K	241.6K	3.2M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	21.7M	3M
Common Stock	41.1K	25.9K	25.6K	23.3K	23.3K	12K
Additional Paid-In Capital	85.5M	69.2M	67.8M	60.5M	60M	0.0
Retained Earnings	-73.9M	-65.4M	-57.2M	-45.5M	-38.6M	-183.1K
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	-21.7M	-3M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	12K
Total Stockholders' Equity	11.7M	3.8M	10.6M	15.1M	21.4M	-171.1K
Total Equity	11.7M	3.8M	10.6M	15.1M	21.4M	-171.1K
SUMMARY
Total Liabilities & Equity	12.1M	4.1M	11.7M	15.6M	21.7M	3M
Total Debt	0.0	0.0	0.0	0.0	0.0	201.3K
Net Debt	-11.6M	-3.1M	-11.2M	-14.5M	-20M	-2.8M
Shares Outstanding	41,084,731	41,084,731	41,084,731	41,084,731	41,084,731	41,084,731

SEC Filings

ANEB - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2025 N/A	December 22, 2025	December 22, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 13, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 13, 2025	November 13, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 29, 2025	September 29, 2025	2025	View Filing
10-K 10-K 2025 FY FY	September 29, 2025	June 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 12, 2025	September 12, 2025	2025	View Filing
8-K 8-K 2025 N/A	July 23, 2025	July 23, 2025	2025	View Filing
10-Q 10-Q 2025 Q1 Q1	May 13, 2025	March 31, 2025	2025	View Filing
8-K 8-K 2025 N/A	May 13, 2025	May 13, 2025	2025	View Filing
8-K 8-K 2025 N/A	April 15, 2025	April 11, 2025	2025	View Filing

Showing 1 to 10 of 76 filings

Related Guides

Blog Categories

Continue your ANEB research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.